Across TCGA pan-cancer cohorts, ZNF396 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF396 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZNF396 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF396 expression acts as an unfavorable survival marker, although some lineages such as LIHC and UCEC show a favorable association.

OV, LIHC, and UCEC are the cancer types where ZNF396 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.160	0.541	.003	18	view →
LIHC	DFS	Median	II,III,IV	0.502	0.210	<.001	12	view →
UCEC	DFS	Median	All	0.961	0.625	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZNF396 tumor-vs-normal RNA expression · all ZNF396 data types